Novel biomarkers of cardiovascular disease: Applications in clinical practice

被引:110
作者
Lyngbakken, Magnus Nakrem [1 ,2 ]
Myhre, Peder Langeland [1 ,2 ]
Rosjo, Helge [1 ,2 ]
Omland, Torbjorn [1 ,2 ]
机构
[1] Akershus Univ Hosp, Div Med, Postboks 1000, N-1478 Lorenskog, Norway
[2] Univ Oslo, Ctr Heart Failure Res, Oslo, Norway
关键词
Biomarker; cardiovascular disease; prognosis; diagnosis; CARDIAC TROPONIN-T; C-REACTIVE PROTEIN; GROWTH-DIFFERENTIATION FACTOR-15; ACUTE MYOCARDIAL-INFARCTION; ACID-BINDING PROTEIN; ACUTE CORONARY SYNDROME; LONG-TERM MORTALITY; BRAIN NATRIURETIC PEPTIDE; CHRONIC HEART-FAILURE; ATRIAL-FIBRILLATION INSIGHTS;
D O I
10.1080/10408363.2018.1525335
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Measurement of biomarkers has revolutionized the work-up of patients with suspected cardiovascular disease. The most widely used contemporary cardiovascular biomarkers are the natriuretic peptides in the diagnosis and prognosis of heart failure and cardiac troponins in the diagnosis of acute myocardial infarction. Numerous other biomarkers pertaining to diagnosis, prognosis, and risk prediction have been identified, but few have made their way to clinical practice. In this review, we will initially describe the fundamental approach to evaluate a novel biomarker. Before implementation of a biomarker into clinical practice, several stringent criteria related to its clinical utility are required. Essential statistical metrics such as discrimination, calibration, and reclassification are required to properly evaluate prediction models. We will then discuss the biomarkers according to main groups of cardiovascular pathology:1. myocardial injury (cardiac troponins, heart-type fatty acid-binding protein, cardiac myosin binding protein-C);2. myocardial stress (A-type and B-type natriuretic peptides, mid-regional pro-adrenomedullin, copeptin); 3. inflammation (C-reactive protein, interleukin 6, growth differentiation factor 15, soluble suppressor of tumorigenicity 2, galectin-3);4. platelet activation (soluble CD40 ligand, P-selectin);5. plaque instability (lipoprotein-associated phospholipase A(2), matrix metalloproteinase-9);6. systemic stress (catecholamines, granin proteins);7. calcium homeostasis (secretoneurin). Finally, we will discuss novel applications of cardiovascular biomarkers, more specifically prediction of ventricular arrhythmias, and the use of biomarkers in composite risk prediction models.
引用
收藏
页码:33 / 60
页数:28
相关论文
共 354 条
[1]   Biochemical risk markers and 10-year incidence of atherosclerotic cardiovascular disease: independent predictors, improvement in pooled cohort equation, and risk reclassification [J].
Akintoye, Emmanuel ;
Briasoulis, Alexandros ;
Afonso, Luis .
AMERICAN HEART JOURNAL, 2017, 193 :95-103
[2]   Preventing myocardial infarction in the young adult in the first place: How do the National Cholesterol Education Panel III guidelines perform? [J].
Akosah, KO ;
Schaper, A ;
Cogbill, C ;
Schoenfeld, P .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (09) :1475-1479
[3]   Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides [J].
Ala-Kopsala, M ;
Magga, J ;
Peuhkurinen, K ;
Leipälä, J ;
Ruskoaho, H ;
Leppäluoto, J ;
Vuolteenaho, A .
CLINICAL CHEMISTRY, 2004, 50 (09) :1576-1588
[4]   Myocardial infarction redefined -: A consensus Document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction [J].
Alpert, JS ;
Antman, E ;
Apple, F ;
Armstrong, PW ;
Bassand, JP ;
de Luna, AB ;
Beller, G ;
Breithardt, G ;
Chaitman, BR ;
Clemmensen, P ;
Falk, E ;
Fishbein, MC ;
Galvani, M ;
Garson, A ;
Grines, C ;
Hamm, C ;
Jaffe, A ;
Katus, H ;
Kjekshus, J ;
Klein, W ;
Klootwijk, P ;
Lenfant, C ;
Levy, D ;
Levy, RI ;
Luepker, R ;
Marcus, F ;
Näslund, U ;
Ohman, M ;
Pahlm, O ;
Poole-Wilson, P ;
Popp, R ;
Alto, P ;
Pyörälä, K ;
Ravkilde, J ;
Rehnquist, N ;
Roberts, W ;
Roberts, R ;
Roelandt, J ;
Rydén, L ;
Sans, S ;
Simoons, ML ;
Thygesen, K ;
Tunstall-Pedoe, H ;
Underwood, R ;
Uretsky, BF ;
Van de Werf, F ;
Voipio-Pulkki, LM ;
Wagner, G ;
Wallentin, L ;
Wijns, W .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (03) :959-969
[5]   Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes [J].
Ammann, P ;
Maggiorini, M ;
Bertel, O ;
Haenseler, E ;
Joller-Jemelka, HI ;
Oechslin, E ;
Minder, EI ;
Rickli, H ;
Fehr, T .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (11) :2004-2009
[6]   Cardiac myosin-binding protein C is a novel marker of myocardial injury and fibrosis in aortic stenosis [J].
Anand, Atul ;
Chin, Calvin ;
Shah, Anoop S. V. ;
Kwiecinski, Jacek ;
Vesey, Alex ;
Cowell, Joanna ;
Weber, Ekkehard ;
Kaier, Thomas ;
Newby, David E. ;
Dweck, Marc ;
Marber, Michael S. ;
Mills, Nicholas L. .
HEART, 2018, 104 (13) :1101-1108
[7]   Serial Measurement of Growth-Differentiation Factor-15 in Heart Failure Relation to Disease Severity and Prognosis in the Valsartan Heart Failure Trial [J].
Anand, Inder S. ;
Kempf, Tibor ;
Rector, Thomas S. ;
Tapken, Heike ;
Allhoff, Tim ;
Jantzen, Franziska ;
Kuskowski, Michael ;
Cohn, Jay N. ;
Drexler, Helmut ;
Wollert, Kai C. .
CIRCULATION, 2010, 122 (14) :1387-+
[8]   C-reactive protein in heart failure - Prognostic value and the effect of valsartan [J].
Anand, IS ;
Latini, R ;
Florea, VG ;
Kuskowski, MA ;
Rector, T ;
Masson, S ;
Signorini, S ;
Mocarelli, P ;
Hester, A ;
Glazer, R ;
Cohn, JN .
CIRCULATION, 2005, 112 (10) :1428-1434
[9]   Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT) [J].
Anand, IS ;
Fisher, LD ;
Chiang, YT ;
Latini, R ;
Masson, S ;
Maggioni, AP ;
Glazer, RD ;
Tognoni, G ;
Cohn, JN .
CIRCULATION, 2003, 107 (09) :1278-1283
[10]   CaMKII in myocardial hypertrophy and heart failure [J].
Anderson, Mark E. ;
Brown, Joan Heller ;
Bers, Donald M. .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2011, 51 (04) :468-473